Chandra Preeti, Roldao Marisa, Drachenberg Cinthia, Santos Paulo, Washida Naoki, Clark Alexander, Bista Bipin, Mitsuna Ryunosuke, Yango Angelito
Division of Nephrology, University of Maryland, Baltimore, MD, USA.
Department of Nephrology, Centro Hospitalar do Médio Tejo, Torres Novas, Portugal.
Clin Nephrol Case Stud. 2022 Jul 21;10:54-63. doi: 10.5414/CNCS110924. eCollection 2022.
There have been multiple reports of the development of de novo or relapse of glomerular diseases after SARS-CoV-2 vaccination. While most of them have occurred with the mRNA vaccines (Pfizer/BioNTech and Moderna/NIAID), there also have been reports associated with the vector vaccines (AstraZeneca/ChAdOx1-S) vaccine and the inactivated vaccines. Minimal change disease (MCD) is one of the more common glomerular diseases noted to have been associated with the COVID-19 vaccination. We report here 4 more cases of MCD occurring in association with the COVID-19 vaccine, 3 were de novo cases, and 1 case had a relapse of MCD. We also review all the 41 cases described thus far in the literature and review potential common pathways activated by the vaccination that play a role in the pathogenesis of MCD.
有多项报告称，接种新型冠状病毒2（SARS-CoV-2）疫苗后出现了新发肾小球疾病或肾小球疾病复发。虽然其中大多数发生在mRNA疫苗（辉瑞/生物新技术公司和莫德纳/美国国立过敏与传染病研究所）接种后，但也有与载体疫苗（阿斯利康/ChAdOx1-S）疫苗和灭活疫苗相关的报告。微小病变性肾病（MCD）是与2019冠状病毒病（COVID-19）疫苗接种相关的较常见肾小球疾病之一。我们在此报告另外4例与COVID-19疫苗相关的MCD病例，其中3例为新发病例，1例为MCD复发。我们还回顾了文献中迄今描述的所有41例病例，并探讨了接种疫苗激活的、在MCD发病机制中起作用的潜在共同途径。
